Chalcones as Novel Non-peptidic μ-Calpain Inhibitors
作者:Eun-Young Lee、In-Hye Jang、Min-Jung Shin、Hee-Ju Cho、Jung-Sook Kim、Ji-Eun Eom、Young-Joo Kwon、Young-Hwa Na
DOI:10.5012/bkcs.2011.32.9.3459
日期:2011.9.20
In order to extend the scaffold of non-peptidic calpain inhibitor, we have designed and synthesized 14 chalcone derivatives categorized into two groups based on their structures. Compounds 7 ($IC_50}=16.67\pm}0.42\mu}M$) and 8 ($IC_50}=16.92\pm}0.14\mu}M$) in group A were most selective $\mu}$-calpain inhibitor over cathepsins B and L. On the other hand, compound 14 possessing furan ring exhibited inhibitory activities for $\mu}$-calpain ($IC_50}=15.39\pm}1.34\mu}M$) as well as cathepsin B ($IC_50}=20.59\pm}1.35\mu}M$). The results discovered implicated that chalcone analogues possessing proper size and functional groups can be a potential lead core for selective non-peptidic $\mu}$-calpain inhibitor. Furthermore, dual inhibitors for $\mu}$-calpain and cathepsin B can also be developed from chalcones by elaborate structure manipulation.
为了扩展非肽类钙蛋白酶抑制剂的支架,我们设计并合成了14种查耳酮衍生物,根据其结构分为两类。化合物 7 ($IC_50}=16.67\pm}0.42\mu}M$) 和 8 ($IC_50}=16.92\pm}0.14\mu A 组中的 }M$) 是比组织蛋白酶 B 和 L 最具选择性的 $\mu}$-钙蛋白酶抑制剂。 另一方面,具有呋喃环的化合物 14 对$\mu}$-钙蛋白酶 ($IC_50}=15.39\pm}1.34\mu}M$) 以及组织蛋白酶 B ($IC_50}=20.59\pm}1.35\mu}M$)。研究结果表明,具有适当大小和官能团的查尔酮类似物可以成为选择性非肽$\mu}$-钙蛋白酶抑制剂的潜在先导核心。此外,$\mu}$-calpain 和组织蛋白酶 B 的双重抑制剂也可以通过精细的结构操作从查耳酮中开发出来。
The present invention relates to Stilbene derivatives of the general formula I or a pharmaceutically acceptable salt thereof have properties such as high water solubility, bioavailability and effective as carcinostatics.